Trial Profile
A Phase II, Randomized, Placebo-Controlled Study to Evaluate the Immunogenicity and the Safety of 2 Schedules of an Homologous Prime-Boost With the ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV vaccine vCP1452 (Primary)
- Indications HIV infections
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms MANON-02
- 17 Dec 2009 Actual end date (Sep 2006) added as reported by ClinicalTrials.gov.
- 11 Jul 2008 Primary endpoint results published in AIDS in July 2008
- 28 Feb 2007 Results have been reported.